Arvinas, Inc. (NASDAQ:ARVN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Arvinas, Inc. (NASDAQ:ARVN) have been given an average recommendation of “Moderate Buy” by the fourteen brokerages that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and thirteen have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $61.08.

Several equities analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $87.00 price objective on shares of Arvinas in a research report on Thursday, October 31st. BMO Capital Markets cut their price target on shares of Arvinas from $90.00 to $88.00 and set an “outperform” rating on the stock in a report on Wednesday, November 20th. Oppenheimer reduced their price objective on shares of Arvinas from $50.00 to $40.00 and set an “outperform” rating for the company in a research note on Thursday, October 31st. Stephens initiated coverage on shares of Arvinas in a research report on Monday, November 18th. They set an “overweight” rating and a $55.00 target price on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arvinas in a research report on Monday, September 9th.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of ARVN. SG Americas Securities LLC raised its position in Arvinas by 137.2% in the 2nd quarter. SG Americas Securities LLC now owns 86,096 shares of the company’s stock valued at $2,292,000 after purchasing an additional 49,799 shares during the last quarter. Candriam S.C.A. raised its holdings in shares of Arvinas by 32.0% in the second quarter. Candriam S.C.A. now owns 610,458 shares of the company’s stock valued at $16,250,000 after buying an additional 147,904 shares during the last quarter. Magnetar Financial LLC lifted its position in Arvinas by 112.7% during the 2nd quarter. Magnetar Financial LLC now owns 41,992 shares of the company’s stock worth $1,118,000 after buying an additional 22,245 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Arvinas by 32.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 235,096 shares of the company’s stock worth $6,258,000 after acquiring an additional 57,835 shares during the last quarter. Finally, Assenagon Asset Management S.A. acquired a new stake in Arvinas in the 3rd quarter valued at about $3,442,000. Institutional investors own 95.19% of the company’s stock.

Arvinas Stock Performance

Arvinas stock opened at $26.72 on Monday. Arvinas has a twelve month low of $21.17 and a twelve month high of $53.08. The firm has a market cap of $1.84 billion, a PE ratio of -5.72 and a beta of 1.96. The firm’s 50 day moving average price is $25.68 and its two-hundred day moving average price is $26.74.

Arvinas (NASDAQ:ARVN) last released its quarterly earnings data on Wednesday, October 30th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.20. The firm had revenue of $102.40 million for the quarter, compared to analyst estimates of $60.56 million. During the same period in the previous year, the business posted ($1.18) EPS. Arvinas’s revenue for the quarter was up 196.0% on a year-over-year basis. Equities analysts anticipate that Arvinas will post -3.24 EPS for the current fiscal year.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.